A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically

Xin shuai Wang, Xue zhen Ding, Xiao cen Li, Yixuan He, De jiu Kong, Li Zhang, Xiao chen Hu, Jun qiang Yang, Meng qi Zhao, She gan Gao, Tzu-Yin Lin, Yuanpei Li

Research output: Contribution to journalArticle

1 Scopus citations


The prognosis of esophageal squamous cell carcinoma is poor. We hereby presented a highly integrated and clinically relevant precision nanomedicine strategy to target ESCC molecularly and physically for significant improvement of the treatment efficacy. We firstly identified PI3K overexpression in patient samples and its relation to poor patient survival. With our highly versatile tumor-targeted drug delivery platform (DCM), we were able to load a potent but toxic docetaxel (DTX) and a PI3K inhibitor (AZD8186) with favorable physical properties. The combination of the DTX-DCM and AZD8186-DCM showed a highly efficacious and synergistic anti-tumor effect and decreased hematotoxicity. A pro-apoptotic protein, Bax was significantly upregulated in ESCC cells treated with combination therapy compared to that with monotherapy. This study utilized a highly integrated precision nano-medicine strategy that combines the identification of cancer molecular target from human patients, precision drug delivery and effective combination therapy for the development of better ESCC treatment.

Original languageEnglish (US)
Pages (from-to)2103-2114
Number of pages12
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Issue number7
StatePublished - Oct 1 2018



  • Docetaxel
  • Esophageal squamous cell carcinoma
  • Nanoparticle
  • PI3K inhibitor
  • Precision nanomedicine

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this